|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, van Ballegooijen M, et al: Annual report to the nation on
the status of cancer, 1975–2006, featuring colorectal cancer trends
and impact of interventions (risk factors, screening, and
treatment) to reduce future rates. Cancer. 116:544–573. 2010.
|
|
3.
|
Mitry E, Bouvier AM, Esteve J and Faivre
J: Benefit of operative mortality reduction on colorectal cancer
survival. Br J Surg. 89:1557–1562. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Mayer RJ: Targeted therapy for advanced
colorectal cancer - more is not always better. N Engl J Med.
360:623–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Siena S, Sartore-Bianchi A, Di
Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting
clinical outcome of epidermal growth factor receptor-targeted
therapy in metastatic colorectal cancer. J Natl Cancer Inst.
101:1308–1324. 2009. View Article : Google Scholar
|
|
6.
|
Bublil EM and Yarden Y: The EGF receptor
family: spearheading a merger of signaling and therapeutics. Curr
Opin Cell Biol. 19:124–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Bose R and Zhang X: The ErbB kinase
domain: structural perspectives into kinase activation and
inhibition. Exp Cell Res. 315:649–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Jura N, Endres NF, Engel K, Deindl S, Das
R, Lamers MH, Wemmer DE, Zhang X and Kuriyan J: Mechanism for
activation of the EGF receptor catalytic domain by the
juxtamembrane segment. Cell. 137:1293–1307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Red Brewer M, Choi SH, Alvarado D,
Moravcevic K, Pozzi A, Lemmon MA and Carpenter G: The juxtamembrane
region of the EGF receptor functions as an activation domain. Mol
Cell. 34:641–651. 2009.PubMed/NCBI
|
|
10.
|
Bill A, Schmitz A, Albertoni B, Song JN,
Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert
L, Schreiber A, et al: Cytohesins are cytoplasmic ErbB receptor
activators. Cell. 143:201–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kolanus W: Guanine nucleotide exchange
factors of the cytohesin family and their roles in signal
transduction. Immunol Rev. 218:102–113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Bos JL, Rehmann H and Wittinghofer A: GEFs
and GAPs: critical elements in the control of small G proteins.
Cell. 129:865–877. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Casanova JE: Regulation of Arf activation:
the Sec7 family of guanine nucleotide exchange factors. Traffic.
8:1476–1485. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Weinstein IB: Cancer. Addiction to
oncogenes - the Achilles heal of cancer. Science. 297:63–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bardelli A and Jänne PA: The road to
resistance: EGFR mutation and cetuximab. Nat Med. 18:199–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Montagut C, Dalmases A, Bellosillo B,
Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S,
Tsai SP, Minoche A, et al: Identification of a mutation in the
extracellular domain of the Epidermal Growth Factor Receptor
conferring cetuximab resistance in colorectal cancer. Nat Med.
18:221–223. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Vlacich G and Coffey RJ: Resistance to
EGFR-targeted therapy: a family affair. Cancer Cell. 20:423–425.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Yonesaka K, Zejnullahu K, Okamoto I, Satoh
T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda
M, Fujisaka Y, et al: Activation of ERBB2 signaling causes
resistance to the EGFR-directed therapeutic antibody cetuximab. Sci
Transl Med. 3:99ra862011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ruan SQ, Wang SW, Wang ZH and Zhang SZ:
Regulation of HRG-β1-induced proliferation, migration and invasion
of MCF-7 cells by upregulation of GPR30 expression. Mol Med Report.
6:131–138. 2012.
|
|
20.
|
El Azreg MA, Garceau V and Bourgoin SG:
Cytohesin-1 regulates fMLF-mediated activation and functions of the
β2 integrin Mac-1 in human neutrophils. J Leukoc Biol. 89:823–836.
2011.
|
|
21.
|
Oh SJ and Santy LC: Differential effects
of cytohesins 2 and 3 on β1 integrin recycling. J Biol Chem.
285:14610–14616. 2010.
|
|
22.
|
Ogasawara M, Kim SC, Adamik R, Togawa A,
Ferrans VJ, Takeda K, Kirby M, Moss J and Vaughan M: Similarities
in function and gene structure of cytohesin-4 and cytohesin-1,
guanine nucleotide-exchange proteins for ADP-ribosylation factors.
J Biol Chem. 275:3221–3230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
El Azreg MA and Bourgoin SG: Cytohesin-1
regulates human blood neutrophil adhesion to endothelial cells
through β2 integrin activation. Mol Immunol. 48:1408–1416.
2011.PubMed/NCBI
|
|
24.
|
Stalder D, Barelli H, Gautier R, Macia E,
Jackson CL and Antonny B: Kinetic studies of the Arf activator Arno
on model membranes in the presence of Arf effectors suggest control
by a positive feedback loop. J Biol Chem. 286:3873–3883. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Chardin P, Paris S, Antonny B, Robineau S,
Béraud-Dufour S, Jackson CL and Chabre M: A human exchange factor
for ARF contains Sec7- and pleckstrin-homology domains. Nature.
384:481–484. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
26.
|
D’Souza-Schorey C and Chavrier P: ARF
proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell
Biol. 7:347–358. 2006.
|
